| 2.325 0.075 (3.35%) | 04-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.92  |
1-year : | 12.84 |
| Resists | First : | 7.64 |
Second : | 11 |
| Pivot price | 3.36 |
|||
| Supports | First : | 2.21 | Second : | 1.83 |
| MAs | MA(5) : | 2.45 |
MA(20) : | 3.68 |
| MA(100) : | 22.44 |
MA(250) : | 233.19 |
|
| MACD | MACD : | -2.3 |
Signal : | -2.7 |
| %K %D | K(14,3) : | 2 |
D(3) : | 2.1 |
| RSI | RSI(14): 25.8 |
|||
| 52-week | High : | 1710 | Low : | 2.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CDT ] has closed above bottom band by 20.0%. Bollinger Bands are 69.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.42 - 2.43 | 2.43 - 2.45 |
| Low: | 2.2 - 2.22 | 2.22 - 2.24 |
| Close: | 2.29 - 2.33 | 2.33 - 2.35 |
CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.
Thu, 30 Apr 2026
CDT Equity (CDT) director discloses 233,585 Common Stock shares on Form 3 - Stock Titan
Mon, 27 Apr 2026
CDT Equity Announces Board Changes and New Chairperson - TipRanks
Mon, 27 Apr 2026
Board reshuffle at CDT Equity (NASDAQ: CDT) adds Ulrik Olsen, new chairs - Stock Titan
Thu, 23 Apr 2026
CDT Equity announces reverse stock split - MSN
Thu, 16 Apr 2026
Tiny Nasdaq biotech links AstraZeneca assets with AI drug hunting - Stock Titan
Thu, 16 Apr 2026
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 73 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -466.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -95.52 |
| Qtrly Earnings Growth | 177.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -2.33 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 92360 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|